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Abstract
Retro-translocation from the ER to the cytosol of proteins within the secretory pathway takes place on misfolded molecules
that are targeted for degradation by the cytosolically located 26S proteasome complex. Retro-translocation occurs also for
other proteins (such as calreticulin) that, despite being synthesized and transported to the ER, are in part dislocated to the
cytosol. We have taken advantage of the E. coli derived biotin-ligase (BirA) expressed in the cytosol of mammalian cells to
specifically biotin-label in vivo proteins within the secretory pathway that undergo retro-translocation. We validated the
method using four different proteins that are known to undergo retro-translocation upon different conditions: the human
trans-membrane protein MHC class-I a chain (MHC-Ia), the Null Hong Kong mutant of the secretory a1 anti-trypsin (NHK-
a1AT), the immunoglobulin heavy chain (HC) and the ER chaperone calreticulin (Crt). We observed specific mono-
biotinylation of cytosolically dislocated molecules, resulting in a novel, reliable way of determining the extent of retro-
translocation.
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Introduction
A critical common feature of the biogenesis of proteins that
enter the secretory pathway, either to be secreted or membrane-
anchored, is transport across the ER membrane to reach the
lumen or to be inserted into membranes [1]. Once in the ER,
newly synthesized proteins initiate a complex process of folding,
assisted by several ER resident chaperones belonging to different
families, such as the heat shock (Hsp90/Grp94, Hsp70 and Hsp40
[2]) and lectin (calnexin, calreticulin [3]) families. In addition,
several covalent post-translational modifications take place within
the ER, that allow the protein to acquire the proper conformation;
these modifications include disulphide bond formation, N-
glycosylation and glycosylphosphatidylinositol (GPI) addition [4].
N-glycosylation is particularly important because it allows the
interaction with molecular chaperones that assist glycoprotein
folding, increasing protein solubility and avoiding the formation of
protein aggregates. When acquisition of the correct folding fails,
misfolded molecules become substrates of the quality control
cellular mechanism known as ER-associated degradation (ERAD
[5]).
Molecules targeted to ERAD, upon recognition by ER lectins,
such as OS-9 and XTP3-B, and molecular chaperones, such as
Hsp70 (BiP) or GRP94 [6,7], are retro-translocated to the cytosol,
a process also known as dislocation, for degradation by the 26S
proteasome complex [8]. Retro-translocation operates also for
proteins, such as calreticulin, that despite being synthesized and
transported to the lumen of the ER, entail other functions in the
nuclear/cytosolic compartments [9].
The mechanism of retro-translocation itself, as well as the
composition of the channel involved during transport is poorly
understood. Sec61, the main component of the translocon for
translocation into the ER of newly synthesized proteins [10], has
been associated to the putative retro-translocon channel as well
[11]. However, other proteins like Der1p and Hrd1p in yeast and
the family of Derlin proteins in mammals have also been described
as candidate constituents of the channel [12,13,14]. TRAM1,
previously characterized for its function during translocation of
nascent polypeptides in the ER [15], has recently been involved in
the disposal of misfolded membrane proteins, but not of soluble
ERAD substrates [16]. In addition BAP31, a three membrane
spanning ER protein, previously demonstrated to be involved in
protein sorting [17], has been found to interact with the Sec61
translocon and described to be implicated in retro-translocation
[18].
Detection of retro-translocated molecules relies usually on the
separation of the cytosolic fraction and identification of de-
glycosylated proteins accumulated in the cytosol upon proteasome
inhibition [19,20], although a tightly coupling of degradation to
dislocation may hamper their detection. A limitation of this
technique could be represented by a low efficiency in the detection
of retro-translocated substrates, because of incomplete proteasome
inhibition or the inability to identify possible glycosylated, yet
retro-translocated molecules. In an attempt to improve the
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of specific in vivo labeling of retro-translocated proteins, by selective
biotinylation in the cytosolic compartment.
Biotinylation of proteins in vivo can be achieved by co-expression
of the E. coli derived biotin-ligase BirA [21] and the protein of
interest tagged with a 15 aa long biotin-acceptor-peptide (BAP): this
peptide contains a single lysine which is efficiently biotinylated by
BirA [22]. We have previously shown that, because of its cytosolic
localization, BirA needs to be engineered with a signal leader
peptide, in order to translocate to the ER and to achieve efficient
biotinylation of proteins within the secretory pathway [23].
Here we show, instead, that co-expressing cytosolic BirA (cyt-BirA)
with defined BAP-tagged membrane bound or secretory proteins,
resultsin biotin-labeling onlyofmolecules dislocated to the cytosol, thus
representing a simple, reliable and quantitative way of determining the
extent of retro-translocation for proteins that have entered ERAD or
proteins that need to dislocate to reach other cellular compartments.
Results
Fusion of the 15 aa long BAP tag (GLNDIFEAQKIEWHE) to a
protein makes possible its mono-biotinylation when co-expressed
in the same cellular compartment with the E. coli BirA. If the
protein of interest is BAP-tagged in the region located to the
luminal side of the ER, it will not be biotinylated by a cytosolically
localized BirA (cyt-BirA), unless it is retro-translocated to the
cytosol. Therefore, the addition of the BAP tag allows the rapid
biotinylation of misfolded membrane-bound or secretory proteins
that enter the ERAD pathway for proteasomal degradation, as
well as of ER synthesized proteins that have functions also in the
cytosol or nucleus after retro-translocation to the cytosol, such as
calreticulin (Fig. 1a).
In order to test the system we used four different model
molecules: the A2 allele of the human major histocompatibility
complex class-I a chain (MHC-Ia), the Null Hong Kong (NHK)
mutant of the secretory a1 anti-trypsin (NHK-a1AT), the Ig heavy
chain (HC) and the ER chaperone calreticulin (Crt). The MHC-Ia
is a type-I trans-membrane protein and a well-known substrate of
ERAD that undergoes retro-translocation when co-expressed with
either of the two cytomegalovirus immune evasion proteins US2 or
US11 [19,24]; the NHK-a1AT is a natural truncated version of
the wild type protein (a1AT) that is not secreted and is also
substrate of ERAD [25], while the Ig HC, when expressed in the
absence of the Ig light chain (LC), is not secreted because of its
Figure 1. Scheme of in vivo biotinylation of retro-translocated proteins and of genetic constructs. (a), membrane or secretory proteins
with the BAP-tag localized to the luminal side of the ER. Upon retro-translocation the cytosolic BirA covalently adds a biotin to the single acceptor lysine
within BAP. (b), scheme of the principal constructs used. The BAP and SV5 tags are indicated. In each case the signal leader peptide (sec) is indicated.
doi:10.1371/journal.pone.0023712.g001
Biotinylation of Retro-Translocated Proteins
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23712association with the ER resident chaperone grp78/BiP [26]. Crt
instead, is an ER chaperone and the major Ca
2+-binding protein
within the ER lumen that, following retro-translocation, has
regulatory functions both in the cytosolic and nuclear compart-
ments [27,9].
A schematic diagram of all the genetic constructs used is shown
in Fig. 1b. The type-I transmembrane MHC-Ia was tagged with
the BAP peptide at the N-terminus (BAP-MHC-Ia), therefore
localizing the tag to the lumen of the ER, so that it cannot be
biotinylated by cyt-BirA unless it gets retro-translocated to the
cytosol. As a positive control, a C-terminus BAP-tagged version
(MHC-Ia-BAP) with the BAP exposed to the cytosolic side was
also constructed. Similarly, Crt was BAP-tagged at the N-terminus
to avoid disturbing the C-terminal ER-retention signal KDEL.
Instead, the NHK-a1AT as well as wild type a1AT (a1AT) and
HC were tagged at the C-terminus. In all cases the 12 aa long SV5
tag was also included to favor recognition.
Biotinylation was monitored either by ELISA or by a Western
blotting retardation assay (WB-ra) where samples, following
denaturation, are run in the presence of streptavidin (StrAv). In
this latter assay the complex formed by StrAv and biotinylated
molecules is resistant to the SDS-PAGE denaturing conditions and
therefore migration is retarded in relation to the non-biotinylated
ones that do not bind StrAv.
Retro-translocation of MHC-Ia
Fig. 2 shows an analysis by WB-ra of total cellular extracts
from HEK293 cells co-transfected with cyt-BirA and either the
N- or C-terminus BAP tagged MHC-Ia. As expected, while BAP-
MHC-Ia was essentially not biotinylated, C-tagged MHC-Ia-
BAP yielded complete biotinylation (Fig. 2a). Likewise, BAP-
MHC-Ia was almost completely biotinylated by a previously
described engineered version of BirA containing an N-terminal
leader signal peptide (sec-BirA) that localizes to the ER [23]
(Fig. 2a). When BAP-MHC-Ia was co-expressed with cyt-BirA
and either of the two immunoevasins US2 and US11 to induce
retro-translocation and degradation, a significant increase in the
amount of biotinylated BAP-MHC-Ia (as compared to co-
expression with an irrelevant protein) was observed, despite a
reduction in the total amount of BAP-MHC-Ia (Fig. 2b),
suggesting that molecules biotinylated by cyt-BirA corresponded
to the retro-translocated ones. This was confirmed by co-
expressing BAP-MHC-Ia with three different retro-translocation
incompetent mutants, namely, US11-Q192L [12], US2-C133S
[28] and US2-DC (lacking the cytosolic domain aa 186–199
[29]), which did not affect MHC-Ia expression and showed much
lower biotinylation levels than wild type immunoevasins (Fig. 2b).
This is therefore a clear indication that the biotinylated material
actually represents molecules exposed to the cytosol that become
substrate of cyt-BirA. This conclusion was further supported by
cytofluorimetric analysis of the mature, cell-surface exposed
MHC-Ia co-expressed with cyt-BirA (and US2 or US11) or sec-
BirA (Fig. 2c). Levels of MHC-Ia on the cell membrane were
reduced, as expected, when co-expressed with either US2 or
US11, but were not affected by co-expression of cyt-BirA or sec-
BirA, as revealed by detection with anti-SV5 antibody (Fig. 2c,
left panel). When the same set of transfected cells was instead
analysed with streptavidin-QuantumDot to exclusively detect
biotin-labeled MHC-Ia, positive staining was observed only when
co-expressed with sec-BirA and not with cyt-BirA (Fig. 2c, right
panel). Thus, in cells expressing cyt-BirA all the MHC-Ia exposed
on the cell surface (regardless whether expressed alone or with
US2 or US11) was not biotinylated, further demonstrating the
intracellular localisation of the biotinylated molecules. Further-
more, when a negative control secretory BAP-bearing protein
(scFv-BAP [23]), which does not interact with US2 or US11, was
co-expressed with BAP-MHC-Ia,c y t - B i r Aa n dU S 2o rU S 1 1t h e
secreted material was found not biotinylated, although somehow
reduced with US11 (Fig. 2d), thus confirming the specificity of
biotinylation in the cytosolic compartment. Similarly, a truncated
version of human membrane IgE, irrelevant to US2 or US11,
that is otherwise fully biotinylated by sec-BirA [23], was also
essentially not biotinylated by cyt-BirA (Fig. 2e). The small
amount of biotinylated molecules found with US2 was likely due
to the immunoevasin induced cellular stress.
These results demonstrated that: i) the BAP tag is fully sensitive
to biotinylation when localized to the same cellular compartment
as the BirA enzyme, and ii) molecules within the ER lumen, either
membrane bound or secretory, are protected from the biotinylat-
ing activity of cytosolic BirA. A small fraction of biotinylated BAP-
MHC-Ia, when expressed either alone or with an irrelevant
protein was frequently detected, most likely representing the
fraction of misfolded molecules that have spontaneously entered
the ERAD pathway. This was not due to post-lysis biotinylation
since cellular extracts were prepared by directly resuspending cells
in hot, SDS-containing lysis buffer to immediately denature
proteins and block the activity of cyt-BirA.
Results similar to the ones shown above with WB-ra were also
obtained by performing [
35S]-Methionine pulse-chase labeling
experiments, followed by analysis of immunoprecipitated MHC-
Ia in a PAGE retardation assay. As shown in Fig. S1, while in
cells expressing US2 30% of the [
35S]-Methionine-labeled
MHC-Ia was biotinylated after the 30 min pulse labeling
period, the proportion of biotinylated molecules increased to
around 55% after the 2 h chase, despite a decrease in total
MHC-Ia.
Proteasome inhibition increases biotinylation of MHC-Ia
The results shown above indicate that biotinylated MHC-Ia
corresponds to the fraction dislocated to the cytosol and not yet
degraded by the proteasome. To further support this interpre-
tation we tested the effect of proteasome inhibitors MG132
(50 mM for 4 h) and Bortezomib (50 mM for 4 h). As shown in
Fig. 3 upon proteasome inhibition an increased amount of
around 5–6 fold of biotinylated molecules was detected, both in
the absence and presence of US2 and US11 (Fig. 3a). In addition,
although the total amount of BAP-MHC-Ia was reduced when
either US2 or US11 were present, the proportion of biotinylated
molecules accumulated upon proteasome inhibition was much
increased. Quantification of the relative intensities between
retarded (biotinylated) and non-retarded bands of Fig. 3a
(displayed in Fig. 3b) showed in fact that, while less than 1% of
BAP-MHC-Ia expressed alone was found biotinylated in non-
treated cells, upon proteasome inhibition this proportion
increased to 3–4% with MG132 or Bortezomib; when co-
expressed with US2 or US11 the proportion of biotinylation
raised from 13% (US2)–27% (US11) up to 43–52% following
proteasome inhibition (Fig. 3b).
For MHC-Ia, it has been shown that, after dislocation in U373
cells, de-glycosylation by the cytosolically localized cellular PNGase
takes place just before engagement by the proteasome, although de-
glycosylation appears not to be essential for retro-translocation [30].
In HEK293 cells de-glycosylated MHC-Ia w a sl e s sa p p a r e n t ,
particularly with US11. In the presence of proteasome inhibitors
(Fig. 3a), a band corresponding to de-glycosylated material was more
evident and found to be, as expected, completely biotinylated.
However, within the glycosylated fraction, a consistent amount was
also biotinylated. Indeed, Fig. 3c shows the composition of
Biotinylation of Retro-Translocated Proteins
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23712biotinylated MHC-Ia, after affinity-purification with StrAv-coated
beads from extracts of cells co-expressing US2, incubated with or
without MG132. The presence of de-glycosylated material, in
addition to a relevant amount of glycosylated one was clearly seen
from MG132-treated samples (right panel), while in the absence of
MG132, MHC-Ia was mostly glycosylated. In vitro PNGaseF
treatment in both cases was used to confirm the state of glycosylation
of the purified material. Similar results were obtained for US11. This
demonstrates that a significant number of molecules already retro-
translocated to the cytosol and not yet de-glycosylated (also evident in
Figure S1) have already become biotinylated. These results also
indicate that in these cells retro-translocation occurs more rapidly
than de-glycosylation, which can therefore be considered the rate-
limiting step.
Figure 2. Retro-translocation of MHC-Ia. WB-ra of cellular extracts of HEK293 cells transfected with: (a) BAP-MHC-Ia and MHC-Ia-BAP, co-
expressed with cyt-BirA, or BAP-MHC-Ia co-expressed with sec-BirA, as indicated; (b) BAP-MHC-Ia and cyt-BirA and US2 or the US2 mutants US2-DC
and US2-C133S (left panel), or US11 or US11 mutant US11-Q192L (right panel), as indicated. (c) Cytofluorimetry of HEK293 cells co-transfected with
BAP-MHC-Ia and either cyt-BirA (alone or with US2 and US11), or sec-BirA, and stained with anti-SV5 mAb (left panel) or Streptavidin-QuantumDot
(right panel). (d) WB-ra of supernatants of HEK293 cells co-transfected with a secretory BAP-tagged scFv control protein and cyt-BirA, BAP-MHC-Ia and
US2 or US11. (e) WB-ra of cellular extracts of HEK293 cells co-transfected with t-BAP-mIgE, cyt-BirA and US2 or US11, as indicated. All blots were
developed with anti-SV5 mAb, and anti-tubulin where indicated.
doi:10.1371/journal.pone.0023712.g002
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To further demonstrate the specificity of biotinylation occurring
only on molecules that have been exposed to the cytosolic side,
trypsin-sensitivity experiments were performed on microsomes-
containing cell lysates. Cells co-expressing MHC-Ia, cyt-BirA and
US2 or US11 were gently lysed in an appropriate buffer to preserve
the ER structure and then treated with trypsin. As shown in Fig. 4,
the non-biotinylated material obtained with both US2 (Fig. 4a) or
US11 (Fig. 4b) was trypsin-resistant (except for the removal of the
cytosolic C-terminal tail, that results in a faster migrating band), as
expected for molecules protected because of their localisation in the
luminal side of the ER. The biotinylated material, however, was
degraded by trypsin, thus demonstrating that the biotinylated
MHC-Ia molecules are exposed to the cytosolic side.
Retro-translocation of secretory proteins
We next performed experiments with two different secretory
model proteins, NHK-a1AT and Ig HC, which led to essentially
Figure 3. Proteasome inhibition effect on biotinylation of MHC-Ia. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-
MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 mM for 4 h) or Bortezomib
(Bort.; 50 mM for 4 h). (b) Quantification of the relative levels of biotinylated MHC-Ia shown in (a) calculated as the ratio between biotinylated vs. non-
biotinylated form in a given lane. (c) WB-ra of PNGaseF (PNG) treated, affinity-purified biotinylated BAP-MHC-Ia, derived from MG132-treated and
untreated cells co-expressing US2. All blots were developed with anti-SV5 mAb and where indicated with anti-tubulin. Open arrowheads indicate de-
glycosylated BAP-MHC-Ia.
doi:10.1371/journal.pone.0023712.g003
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secretion-incompetent mutant NHK-a1AT was compared to the
wild type protein. Compromised secretion of NHK-a1AT resulted
in intracellular accumulation with a clear fraction of biotinylated
molecules. In contrast, only a small fraction of intracellular a1AT
was biotinylated, while the secreted material was, as expected,
totally non-biotinylated. A smaller band of a1AT was also
observed, and resulted to be biotinylated, likely representing a
cytosolic fragment. In the presence of the proteasome inhibitor
MG132 a band corresponding to de-glycosylated NHK-a1AT
(confirmed by PNGaseF treatment, Fig. 5b) was detected, that was
obviously fully biotinylated. However, as in the case of MHC-Ia,a
fraction of glycosylated NHK-a1AT was also biotinylated. In
addition, a smaller de-glycosylated band (because insensitive to
PNGaseF) of mutant NHK-a1AT, which most likely corresponds
to the same N-terminal deletion of a1AT shown in Fig. 5a, was
fully biotinylated, consistent with cytosolic localization.
Also for NHK-a1AT the biotinylated fraction corresponded to
cytosolically exposed molecules as shown in Fig. 5c. When
microsomes-containing lysates prepared from cells co-expressing
NHK-a1AT and cyt-BirA were treated with trypsin, the non-
biotinylated material was trypsin-resistant, as it corresponds to ER
protected molecules, while the whole fraction of biotinylated
molecules was trypsin-sensitive.
In contrast, when microsome membranes were solubilized by
detergent treatment (NP40), both biotinylated and non-biotiny-
lated molecules became trypsin-sensitive. The biotinylated pro-
teolytic fragments (containing SV5-BAP) generated by trypsin
bound to StrAv and migrated as a smear roughly in the same
position of NHK-a1AT (Fig. 5c, lanes 4, 6).
Expression of the second secretory model protein, Ig cHC, in the
absence of LC resulted in no secretion and in the appearance of a
significant amount of intracellular biotinylated molecules. In contrast,
co-expression with LC promoted, as expected, active secretion of
non-biotinylated HC and a very reduced level of the intracellular
biotinylated fraction, confirming that the presence of LC rescues HC
from ERAD, reducing the extent of retro-translocation (Fig. 5d).
Retro-translocation of calreticulin
Finally, we determined the level of biotinylation associated to
the spontaneous retro-translocation of Crt and compared to the
dislocation-incompetent mutant (Crt-DC), which lacks the 115
residues long C-terminal portion. As shown in two different
representative experiments in Fig. 6, up to 30% of Crt was
biotinylated, in agreement with active dislocation activity and with
the relative abundance of dislocated Crt reported [9]. In contrast,
less than 5% dislocation was observed for Crt-DC. As expected,
however, both of them were almost fully biotinylated by sec-BirA
(Fig. 6b). In addition, a number of smaller fragments (representing
deletions from the C-terminus since the tag was at the N-terminus)
was sometimes detected (Fig 6a, experiment 1) for Crt, but not for
the Crt-DC mutant. These fragments appeared not to be
generated by cytosolic proteases, since they were not biotinylated
when co-expressed with cyt-BirA, but were so with sec-BirA (not
shown).
Determination of retro-translocation by ELISA
Biotinylation also allows detection and quantification by ELISA
of the level of retro-translocation as well as the proportion of
dislocated molecules. We show it for MHC-Ia. The assay was set
up by coating plates with anti-SV5 to capture all MHC-Ia
molecules regardless of their state of biotinylation, and then
revealed: i) with HRP-conjugated StrAv to determine the level of
biotinylation, or ii) with HRP-conjugated StrAv (for the biotiny-
lated fraction) and in parallel, with a second antibody (for the total
amount of protein) to determine the proportion of retro-
translocated molecules (Fig. 7a). In our case we used a BAP-
MHC-Ia construct that contained, in addition to the SV5 at the
N-terminus, a second tag (roTag) at the C-terminus (BAP-MHC-
Ia-roTag). To normalize the assay, we used an extract of cells co-
transfected with the same BAP-MHC-Ia-roTag construct and sec-
BirA, since in that case all molecules are biotinylated. The extent
of retro-translocation was therefore determined as the fraction of
biotinylated molecules (revealed with StrAv) relative to the total
amount of MHC-Ia in the sample (revealed with anti-roTag).
Fig. 7b shows the levels of biotinylation of MHC-Ia expressed with
US2 or US11 in the absence and presence of MG132, while Fig. 7c
shows a plot of the percentage of dislocated MHC-Ia in cells co-
expressing US2 or US11. The values in Fig. 7c are consistent with
those obtained, for the same samples, with the WB-ra (Fig. 7d).
Taken together the data obtained with the different models
demonstrated that biotinylation by cyt-BirA of proteins within the
Figure 4. Trypsin sensitivity of biotinylated MHC-Ia. WB-ra of microsomes-containing cell lysates (microsomes) derived from cells expressing
BAP-MHC-Ia, cyt-BirA and US2 or US11 and treated or not with trypsin, as indicated. As a control, an aliquot of cells was directly lysed in SDS sample
buffer (total). Before lysis cells were treated with 10 mM MG132 for 16 h. Open arrowheads indicate de-glycosylated molecules, while arrows indicate
MHC-Ia with the cytosolic C-terminal tail digested by trypsin.
doi:10.1371/journal.pone.0023712.g004
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23712Figure 5. Retro-translocation of secretory proteins. WB-ra of supernatants and/or cellular extracts, as indicated, of HEK293 cells co-transfected
with: (a), a1AT-BAP or the mutant NHK-a1AT-BAP and cyt-BirA; (b), NHK-a1AT-BAP and cyt-BirA in the presence of MG132 (10 mM for 16 h) and
digested or not (mock) with PNGaseF. Open arrow and arrowheads indicate de-glycosylated full-length NHK-a1AT-BAP and NHK-a1AT-BAP
fragments, respectively, while filled arrow and arrowheads indicate the corresponding biotinylated bands. (c) WB-ra of microsomes-containing cell
lysates (microsomes) derived from cells expressing NHK-a1AT-BAP and cyt-BirA and treated with MG132 (10 mM for 16 h) and, where indicated,
digested with trypsin. NP40 indicates the same microsomes-containing lysates treated with detergent to solubilise ER membranes, thus making also
luminal proteins accessible to trypsin. (d) WB-ra of supernatants and cellular extracts from cells expressing HC-BAP (HC) and cyt-BirA with (+)o r
without (2) LC. All blots were developed with anti-SV5 mAb or anti-tubulin; the LC in (d), left panel, was visualized because of the secondary anti-
mouse IgG antibody used.
doi:10.1371/journal.pone.0023712.g005
Figure 6. Retro-translocation of calreticulin. (a) WB-ra of cellular extracts (developed with anti-SV5 mAb) of HEK293 cells co-transfected with Crt
or the mutant Crt-DC and cyt-BirA. Two representative different experiments are shown. (b) Quantification of the relative levels of biotinylation of Crt
and Crt-DC (obtained from the WB-ra) when co-expressed with cyt-BirA or sec-BirA. Histograms show the results of three independent experiments;
error bars indicate one standard deviation.
doi:10.1371/journal.pone.0023712.g006
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highly specific for molecules that have been retro-translocated
from the ER to the cytosol, thus representing a fast and reliable
way to determine the extent of ER-to-cytosol retro-translocation.
Discussion
Biotinylation of proteins, either chemical or enzymatic, is a
widely used technology with a variety of applications in biological
research. Enzymatic biotinylation, however, offers the possibility
to be implemented in vivo to achieve specific labeling of pre-defined
proteins that have been properly tagged with the 15 aa-long biotin
acceptor peptide BAP [22], which contains a single lysine as a
biotin acceptor residue. The in vivo biotinylation in mammalian
cells by the E. coli derived BirA is highly efficient and specific for
the BAP peptide, resulting in a mono-biotinylated product. We
have previously shown that cyt-BirA co-expressed with a
cytosolically located protein (rotavirus NSP5) resulted in complete
biotinylation of the target [23]. Similarly, the MHC-Ia-BAP, with
the BAP tag localized to the cytosolic side was completely
biotinylated by cyt-BirA. In addition, biotinylation is extremely
stable: the only de-biotinylating activity in cells takes place on
short peptides derived from degraded proteins and in particular by
the activity of biotinidase, an enzyme that removes biotin from
biocytin (Biotinyl-L-lysine [31]). In fact, we observed no decrease
in the amount of biotinylated proteins present in cellular extracts
following incubation of lysates for several hours. In our method we
exploit all these characteristics of BirA in addition to its cytosolic
localization, to specifically label molecules that undergo ER-to-
cytosol retro-translocation.
Using the four different model-proteins selected, that represent
well-known examples of dislocation, we showed that biotinylation
identifies retro-translocated molecules for different types of
proteins (membrane-bound, secretory and ER proteins). Taken
together the data we presented clearly demonstrate that only
molecules exposed to the cytosolic side become substrate of BirA
and therefore biotinylated. Biotin labeling allows, either by the
WB-ra or by ELISA, to precisely establish the fraction of
biotinylated molecules, making therefore possible to determine
the level of retro-translocation for a given protein in different
conditions, as well as to compare the relative folding efficiency of
different proteins or of the same protein in different cells. For
instance, we have observed that, while in HEK293 and HeLa cells
US2 induces a higher level of MHC-Ia degradation than US11, in
CHO cells US11 performs significantly better than US2.
So far, just a few techniques have been described for the
detection of retro-translocated molecules in the presence of
proteasome inhibitors, to favor accumulation of retro-translocated
molecules. For example, retro-translocation of MHC-Ia, and also
of other proteins, is usually identified as the fraction of cytosolic
de-glycosylated intermediates, which requires the use of protea-
some inhibitors to accumulate [30,20]. In contrast, our method
was able to detect a significant amount of biotinylated molecules of
MHC-Ia as well as secretory NHK-a1AT and HC that were still
glycosylated, even in the absence of proteasome inhibition. As
expected, because of their cytosolic localization the few de-
glycosylated molecules detected in the presence of proteasome
inhibitors were completely biotinylated.
Therefore, by in vivo biotinylation it is possible to study the rate
and extent of retro-translocation also for non-glycosylated proteins
and, in general, regardless of the glycosylation status. Moreover,
biotinylation of BAP-tagged proteins can be adapted to in vitro
retro-translocation assays.
We noticed that in HEK293 cells the accumulation of de-
glycosylated MHC-Ia was less relevant than what described for
U373 cells [32], as previously reported also for the non-classical
class I molecule HFE in HEK293 cells [33]. In vivo biotinylation
appears to be very efficient in labeling recently retro-translocated
molecules, well before their de-glycosylation. De-glycosylated
molecules are only detected following proteasome inhibition, thus
suggesting that de-glycosylation is the rate-limiting step in the
degradative pathway. The results obtained indicate that quanti-
fying retro-translocation by considering only de-glycosylated
molecules may result in underestimation of the extent of retro-
translocation. On the other hand, treatment of cells with
proteasome inhibitors can lead, as a consequence of accumulation
of misfolded proteins, to the activation of the unfolded protein
response (UPR), which implies increased expression of proteins
involved in protein folding, such as chaperones, and proteins
directly participating in retro-translocation, such as SEL1L and
Figure 7. Determination of retro-translocation by ELISA. (a)
Scheme of the ELISA used to monitor biotinylation of the retro-
translocated fraction. Anti-SV5 mAb coating ensures capture of both,
biotinylated and not-biotinylated BAP-MHC-Ia, which are then revealed
with HRP-conjugated StrAv (only biotinylated MHC-Ia) and with anti-
roTag (total MHC-Ia). (b) Retro-translocation levels (developed with
HRP-conjugated StrAv) of BAP-MHC-Ia in HEK293 cells transfected alone
or with US2 or US11, in the presence or absence of MG132 (50 mM for
4 h), as indicated. (c) Proportion of retro-translocated BAP-MHC-Ia
(developed in parallel with HRP-conjugated StrAv and anti-roTag) in
HEK293 cells transfected alone or with US2 or US11, expressed as the
fraction of biotinylated BAP-MHC-Ia relative to the total amount of BAP-
MHC-Ia. Histograms show the results of three independent experi-
ments; error bars indicate one standard deviation. (d) WB-ra of samples
used in (c), developed with anti-SV5 mAb or anti-tubulin. The arrow
indicates the position of the non-biotinylated MHC-Ia.
doi:10.1371/journal.pone.0023712.g007
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ment with proteasome inhibitors led to an increase in the amount
of retro-translocated/biotinylated MHC-Ia molecules accumulat-
ed even in the absence of immunoevasins.
Biotinylated molecules can be directly detected by assaying
blotted membranes with StrAv. However, we prefer the
retardation assay because it allows also detection of the non-
biotinylated fraction and of the possible presence of fragments,
which may not be biotin-labeled, as we have observed for Crt. In
this respect, it is not clear what those Crt fragments represent.
They were all derived from deletions of the C-terminus (since the
tag is N-terminally located) with similar or shorter lengths than the
Crt-DC mutant, which lacks 115 aa. It is possible that these
fragments were generated and retained in the ER, and not retro-
translocated. Alternatively, they may result from the activity of
lysosomal proteases participating in degradation of ER material as
a consequence of autophagy [36]. Interestingly, since Crt retro-
translocation appears to be of relevance for its nuclear activity, it
may not be related to the turnover of the protein via proteasomal
degradation. It thus remains an open question whether natural
turnover of Crt involves autophagy rather than proteasomal
degradation.
A further advantage offered by the described technique is the
possibility to affinity purify biotinylated molecules, making possible
the analysis, for instance by mass-spectrometry, of intermediates of
retro-translocation.
In summary, the mono-biotinylation of cytosolically dislocated
molecules here described represents a novel, simple, quantitative
and reliable way of determining the extent of ER-to-cytosol retro-
translocation of proteins in vivo.
Materials and Methods
Ethics statement
An ethics approval for the use of human RNA was not
requested, since the material used was already available from a
previous study [37], and it was obtained at a time when there was
no such requirement.
Constructs
The human MHC-Ia allele A2 cDNA (accession number
U02935) was PCR amplified from RNA extracted from
anonymous healthy donors lymphocytes and inserted into
pcDNA3 expression vectors (Invitrogen) containing the coding
sequences for a secretion signal, the SV5 tag (GKPIPNPLLGLD)
and the biotin acceptor peptide BAP (GLNDIFEAQKIEWHE
[22]). Two plasmids were generated, one containing the SV5 and
BAP sequences at the aminoterminal side of MHC-Ia (pcDNA-
BAP-MHC-Ia) and one with BAP and SV5 sequences fused to the
carboxyterminal side of MHC-Ia (pcDNA-MHC-Ia-BAP, Fig. 1b).
The cDNA for the human a1-antitrypsin (a1AT, accession
number K01396) was similarly PCR amplified and inserted in a
vector that adds the SV5 and BAP sequences at the carbox-
yterminal end (pcDNA-a1AT-BAP, Fig. 1b). The vector express-
ing the NHK mutant of a1AT [38] was generated by substituting
the wild type a1AT sequence in the pcDNA-a1AT-BAP vector
with a sequence containing a two-base deletion after codon 318 of
the mature protein resulting in the insertion of 14 frame-shifted
codons (pcDNA-NHK-a1AT-BAP, Fig. 1b). The plasmid express-
ing the mouse c heavy chain was obtained by inserting the coding
sequence in the pcDNA vector with the SV5 and BAP sequences
at the carboxyterminal end (pcDNA-HC-BAP, Fig. 1b). The
vectors expressing the full-length and truncated calreticulins were
generated by inserting the PCR amplified cDNAs of human
calreticulin (accession number NM_004343) or the calreticulin
truncated after codon 285 of the mature protein in the vector with
the SV5 and BAP sequences at the aminoterminus (pcDNA-BAP-
Crt and pcDNA-BAP-Crt-DC, Fig. 1b).
Cell culture and transfection
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10% fetal calf serum (FCS).
Cells were co-transfected in 6-well plates (about 5610
5 cells/
well) by standard calcium phosphate technique [39]. When
indicated, US2 or US11 plasmids (kindly provided by D.
Tortorella) were co-transfected. In transfection experiments
involving mouse cHC, a vector expressing a mouse kLC was co-
transfected, where required. 18 h after transfection, medium was
discarded and replaced by 2 ml of serum free medium
supplemented with 0.1 mM biotin and further incubated for at
least 8 h. When required, after 4 h incubation with biotin, the
proteasome inhibitors MG132 (Sigma) or Bortezomib (Selleck
Chemicals) were added at a concentration of 50 mM for 4 h, or at
10 mM for 16 h (MG132).
Cell extract preparation, gel retardation assay and
Western blotting
HEK293 transfected cells were lysed directly in the transfection
plates, after collecting medium and washing with PBS to remove
free biotin, with 100 ml/well of SDS-lysis buffer (100 mM Tris-
HCl, pH 6.8, 6% SDS) and subsequently sonicated to disrupt
nuclear DNA. For gel retardation assay, samples denatured in
SDS-gel-loading buffer (25 mM Tris-HCl, pH 6.8, 1% SDS, 10%
glycerol, 175 mM b-mercaptoethanol) were boiled for 10 min,
cooled to RT and incubated with 1 mg of StrAv (Sigma) for 30 min
before separation on SDS-PAGE, then transferred to PVDF
membranes for immunodetection with anti-SV5 mAb followed by
incubation with HRP-labeled anti-mouse whole IgG (Jackson) and
ECL reaction. Quantification of bands was performed with the
image processing software Image-J 1.43u, National Institutes of
Health, USA. Purification of biotinylated MHC-Ia was carried out
by incubating the lysates in SDS-PAGE loading buffer with StrAv-
coated magnetic beads (Dynabeads, Invitrogen) and eluting by
boiling for 10 min. Where indicated, eluted material was treated
with Peptide-N-Glycosidase-F (PNGase-F, New England Biolabs)
according to manufacturer indications.
Cytofluorimetric analysis
Cells were, 24 h after transfection, incubated either with the
anti-SV5 mAb followed by fluorescein-conjugated anti-mouse IgG
(KPL), or with QuantumDot655-Streptavidin (Invitrogen) and
analyzed in a FACSCalibur (Becton Dickinson).
Trypsin sensitivity assay
Microsome-containing lysates were obtained by resuspending
cells in buffer 50 mM Tris-HCl pH 8.0, 250 mM sucrose and
10 mM N-ethyl-maleimide (to block cyt-BirA post-lysis activity),
freezed and thawed once, and centrifuged at 50006g for 5 min at
4uC. Supernatants (microsome-containing lysates) were incubated
with 1 mg trypsin for 1 h at 37uC. When indicated NP40 was
added at 0.5% final concentration.
Quantification of retro-translocation by ELISA
Samples in SDS-lysis buffer were treated with 0.15 M b-
mercaptoethanol and boiled for 10 min. Free b-mercaptoethanol
was then quenched by diluting with an equal volume of
iodoacetamide 0.15 M in buffer Tris-HCl 0.1 M, pH 8.0. Serial
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pH 8.0, 250 mM NaCl, 0.5% NP-40), starting from 10 ml/well,
were applied to polystyrene microplates (Nunc Maxisorp C96)
coated with 0.2 mg/ml of anti-SV5 mAb in buffer NaHCO3-
Na2CO3 50 mM, pH 9.5 (100 ml/well). Proteins were bound to
the plates for 1 h at RT and then reacted with either HRP-labeled
StrAv (Jackson Immunoresearch) or anti-roTag (scFv in SIPeS2
format [40]) followed by HRP-labeled anti-human IgE (KPL), and
developed with TMB reagent (Sigma). After blocking with H2SO4,
the O.D. at 450 nm was read on a BioRad microplate reader 550.
To calculate the proportion of retro-translocated molecules, the
ratio between the slopes derived from the linear region of the serial
dilutions curves developed with StrAv and anti-roTag was first
determined for the 100% biotinylated sample (MHC-Ia co-
expressed with sec-BirA), and termed reference factor, F100. The
same factor was then determined for each sample (Fx). The
biotinylated fraction was thus calculated as (Fx/F100)6100.
Supporting Information
Figure S1 Pulse-chase labeling of retro-translocated
MHC-Ia. PAGE retardation assay of anti-SV5 immunoprecipi-
tated cellular extracts of HEK293 cells co-transfected with BAP-
MHC-Ia and cyt-BirA and, where indicated, with US2. Cells were
starved for 30 min with Methionine/Cysteine free medium,
supplemented with 10% of dialyzed FCS and 0.1 mM biotin,
then labelled for 30 min with 200 mCi/ml [
35S]-Methionine/
Cysteine (Perkin Elmer) and chased in biotin-containing fresh
medium for 120 min. Cells were then lysed in 100 ml of SDS-lysis
buffer, diluted with 400 ml of TNN and digested with DNaseI for
1 h to disrupt DNA. Samples were immunoprecipitated with anti-
SV5 mAb and Protein A-agarose (Repligen) and resolved in a 10%
SDS-PAGE. The arrow indicates the position of the non-
biotinylated MHC-Ia. Right panel, quantification of the BAP-
MHC-Ia biotinylated band, expressed as percentage of the total
immunoprecipitated BAP-MHC-Ia (biotinylated + non - biotiny-
lated). Histograms show the results of three independent
experiments; error bars indicate one standard deviation.
(TIF)
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